Friday, September 4, 2026

Nelnet, Inc. And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 15, 2020

Nelnet, Inc. And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. D.R. Horton, Inc.

30.4% sales growth and 21.24% return on equity

D.R. Horton, Inc. sales growth this year is anticipated to be 22.9% and 11.9% for next year.

Year-on-year quarterly revenue growth grew by 27%, now sitting on 20.31B for the twelve trailing months.

D.R. Horton, Inc.'s sales growth for the next quarter is 30.4%. The company's growth estimates for the present quarter and the next is 44.8% and 41.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.24%.

D.R. Horton, Inc.'s Stock Top and Bottom Yearly Value

D.R. Horton, Inc.'s stock is valued at $70.01 at 04:57 EST, way below its 52-week high of $81.21 and way higher than its 52-week low of $25.51.

D.R. Horton, Inc.'s Moving Average

D.R. Horton, Inc.'s worth is under its 50-day moving average of $72.02 and above its 200-day moving average of $67.73.

2. NIC Inc.

13.8% sales growth and 23.38% return on equity

NIC Inc. sales growth this year is anticipated to be 23.8% and a negative 0.1% for next year.

Year-on-year quarterly revenue growth grew by 48.9%, now sitting on 406.37M for the twelve trailing months.

NIC Inc.'s sales growth for the next quarter is 13.8%. The company's growth estimates for the current quarter and the next is 66.7% and 22.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.38%.

NIC Inc.'s Stock Top and Bottom Yearly Value

NIC Inc.'s stock is valued at $24.38 at 04:57 EST, below its 52-week high of $25.94 and way higher than its 52-week low of $15.49.

NIC Inc.'s Moving Average

NIC Inc.'s worth is above its 50-day moving average of $23.35 and above its 200-day moving average of $22.36.

3. Southwest Gas Corporation

100.8% sales growth and 8.63% return on equity

Southwest Gas Corporation sales growth this year is expected to be 136.8% and 5.7% for next year.

Year-on-year quarterly revenue growth grew by 9.1%, now sitting on 3.23B for the twelve trailing months.

Southwest Gas Corporation's sales growth for the next quarter is 100.8%. The company's growth estimates for the ongoing quarter and the next is a negative 1.8% and 48.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.63%.

Southwest Gas Corporation's Stock Top and Bottom Yearly Value

Southwest Gas Corporation's stock is valued at $63.05 at 04:57 EST, way below its 52-week high of $81.62 and way higher than its 52-week low of $45.68.

Southwest Gas Corporation's Moving Average

Southwest Gas Corporation's worth is under its 50-day moving average of $67.55 and below its 200-day moving average of $67.69.

4. Varian Medical Systems, Inc.

10.3% sales growth and 13.95% return on equity

Varian Medical Systems, Inc. sales growth this year is anticipated to be 12.9% and 9.1% for next year.

Year-on-year quarterly revenue growth declined by 3.2%, now sitting on 3.17B for the twelve trailing months.

Varian Medical Systems, Inc.'s sales growth for the next quarter is 10.3%. The company's growth estimates for the current quarter and the next is a negative 5.2% and 40%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.95%.

Varian Medical Systems, Inc.'s Stock Top and Bottom Yearly Value

Varian Medical Systems, Inc.'s stock is valued at $174.58 at 04:57 EST, below its 52-week high of $176.19 and way higher than its 52-week low of $89.62.

Varian Medical Systems, Inc.'s Moving Average

Varian Medical Systems, Inc.'s worth is above its 50-day moving average of $173.62 and way higher than its 200-day moving average of $156.35.

5. Mid Penn Bancorp

52.5% sales growth and 8.95% return on equity

Mid Penn Bancorp sales growth this year is expected to be 20.8% and 10.9% for next year.

Year-on-year quarterly revenue growth grew by 26.8%, now sitting on 91.31M for the twelve trailing months.

Mid Penn Bancorp's sales growth for the next quarter is 52.5%. The company's growth estimates for the current quarter and the next is 51.9% and 146.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.95%.

Mid Penn Bancorp's Stock Top and Bottom Yearly Value

Mid Penn Bancorp's stock is valued at $24.49 at 04:57 EST, way below its 52-week high of $29.88 and way above its 52-week low of $15.50.

Mid Penn Bancorp's Moving Average

Mid Penn Bancorp's worth is way above its 50-day moving average of $21.99 and way higher than its 200-day moving average of $19.81.

6. Nelnet, Inc.

20.4% sales growth and 6.72% return on equity

Nelnet, Inc. sales growth this year is anticipated to be 44.5% and a negative 16.4% for next year.

Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 1.1B for the twelve trailing months.

Nelnet, Inc.'s sales growth for the next quarter is 20.4%. The company's growth estimates for the current quarter and the next is 406.2% and 291.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.72%.

Nelnet, Inc.'s Stock Top and Bottom Yearly Value

Nelnet, Inc.'s stock is valued at $69.47 at 04:57 EST, under its 52-week high of $73.92 and way higher than its 52-week low of $36.70.

Nelnet, Inc.'s Moving Average

Nelnet, Inc.'s worth is above its 50-day moving average of $67.85 and way above its 200-day moving average of $61.03.

7. Repligen Corporation

43.1% sales growth and 4.04% return on equity

Repligen Corporation sales growth this year is expected to be 30.1% and 28.6% for next year.

Year-on-year quarterly revenue growth grew by 35.4%, now sitting on 327.09M for the twelve trailing months.

Repligen Corporation's sales growth for the next quarter is 43.1%. The company's growth estimates for the present quarter and the next is 55% and 9.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.04%.

Repligen Corporation's Stock Top and Bottom Yearly Value

Repligen Corporation's stock is valued at $180.90 at 04:57 EST, way below its 52-week high of $212.55 and way higher than its 52-week low of $78.41.

Repligen Corporation's Moving Average

Repligen Corporation's value is below its 50-day moving average of $186.11 and way higher than its 200-day moving average of $152.50.

8. BanColombia S.A.

42.3% sales growth and 3.58% return on equity

BanColombia S.A. sales growth this year is anticipated to be 14.7% and 2% for next year.

Year-on-year quarterly revenue growth declined by 0%, now sitting on N/A for the twelve trailing months.

BanColombia S.A.'s sales growth for the next quarter is 42.3%. The company's growth estimates for the ongoing quarter and the next is a negative 68.4% and 2.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.58%.

BanColombia S.A.'s Stock Top and Bottom Yearly Value

BanColombia S.A.'s stock is valued at $37.34 at 04:57 EST, way under its 52-week high of $56.10 and way above its 52-week low of $16.27.

BanColombia S.A.'s Moving Average

BanColombia S.A.'s worth is way higher than its 50-day moving average of $29.55 and way above its 200-day moving average of $27.85.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com